13F Holdings
中文EN

PTIX Protagenic Therapeutics, Inc.\new

Pharmaceutical Preparations · OTC · SEC CIK 1022899 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY168.9%
TTM EPS YoY138.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA155.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets50.8%
Debt / equity0.00x
Current ratio0.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.30x
Accruals ratio201.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue$0$0$0$0$0
R&D expense$901,896$376,740$3.84M$3.06M$1.59M
SG&A expense$332,393$77,530$1.76M$1.21M$1.97M
Operating income-$4.50M-$2.59M-$5.70M-$4.53M-$3.56M
Interest expense———$107,682$137,456
Pretax income$1.37M-$3.59M-$5.53M-$5.00M-$3.56M
Net income$1.37M-$3.59M-$5.53M-$5.00M-$3.56M
EBITDA-$4.45M—-$5.65M-$4.50M-$3.56M
EPS (basic)0.59-0.67-1.13-1.15-0.82
EPS (diluted)0.59-0.67-1.13-1.15-0.82
Weighted avg. shares (diluted)2.33M5.37M4.90M4.34M4.32M
Banking
Net interest income-$1.50M-$1.04M———
Balance sheet
Cash & equivalents$1.51M$14,531$79,568$1.29M$215,189
Short-term investments———$2.77M$7.76M
Inventory—$1,038———
Current assets$1.54M$89,093$1.88M$4.20M$8.04M
PP&E, net$14,556$60,474$73,046$123,332$1,775
Intangibles$2.09M————
Total assets$3.65M$89,093$1.96M$4.32M$8.04M
Current liabilities$1.03M$5.04M$942,759$655,252$1.12M
Total liabilities$1.03M$5.04M$942,759$655,252$1.12M
Shareholders' equity$2.62M-$4.95M-$3.32M$3.67M$6.92M
Shares outstanding1.81M5.80M517,2574.44M4.32M
Cash flow statement
Operating cash flow-$2.81M-$1.77M-$4.22M-$3.70M-$1.99M
Capital expenditure$3,297——$149,775$1,805
Free cash flow-$2.81M——-$3.85M-$2.00M
Investing cash flow$629,883—$2.80M$4.78M$1.60M
Financing cash flow$3.87M$1.81M$1.96M——
Depreciation & amortization$49,215—$50,286$28,218$30
Stock-based compensation$418,589—$923,139$666,828$864,681

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.